Xcorporeal to Present at Roth Capital Partners 2007 New York Conference on September 5th.

LOS ANGELES -- Xcorporeal, Inc., which recently announced a definitive merger agreement with CT Holdings Enterprises, Inc. (OTCBB: CTHE), pursuant to which Xcorporeal will emerge as the surviving entity, today announced that Winson W. Tang, MD, FACP, Chief Operating Officer of the Company will be presenting at the Roth Capital Partners Conference on Wednesday, September 5, 2007 at 4:30 PM Eastern Time. The conference will be held at The Westin New York at Times Square, New York City. The Company's presentation will also be webcast live and archived for future reference at www.wsw.com/webcast/roth13/xcor.

About Xcorporeal, Inc.

Xcorporeal is a development stage medical device company that has developed an innovative platform technology that may potentially replace the function of various human organs. The four products that it plans to market are an ultrafiltration device for patients with congestive heart failure (CHF), devices for home and hospital renal replacement therapy (RRT), and the Wearable Artificial Kidney (WAK). These devices will provide patients with improved, efficient and cost effective therapy. The WAK is a revolutionary device that will enable patients with end-stage renal disease to achieve a quality of life closer to that of healthy individuals. A prototype of the ultrafiltration device and the WAK has been successfully tested in human subjects. The CHF and RRT markets represent multibillion dollar opportunities for Xcorporeal and the Company plans to commercialize the CHF device in 2008.

Forward-Looking Statements

This press release contains forward-looking statements based on current management expectations. Those forward-looking statements include all statements other than those made solely with respect to historical fact. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those expressed in any forward-looking statements. These factors include, but are not limited to, (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; (2) the outcome of any legal proceedings that may be instituted against a party and others following announcement of the merger agreement; (3) the inability to complete the proposed transaction due to the failure to obtain stockholder approval or the failure to satisfy other conditions to completion of the merger, including the receipt of stockholder approval and conditions to the parties' obligations to close, or the termination of the agreement after the merger is effected in the event CT Holdings' common stock does not trade on the Over The Counter Bulletin Board after closing; (4) risks that the proposed transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the transactions; (5) the ability to recognize the benefits of the merger transaction; (6) the amount of the costs, fees, taxes, expenses and charges related to the transactions; and (7) the matters disclosed in the "Risk Factors" sections of the most recent SEC filings by the companies and in the information statement to be filed by the companies, which are available on its website at http://www.sec.gov. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the companies' ability to control or predict. The companies undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.